Michael Cherny
Stock Analyst at Leerink Partners
(4.10)
# 501
Out of 5,050 analysts
119
Total ratings
56.04%
Success rate
11.48%
Average return
Main Sectors:
Stocks Rated by Michael Cherny
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DGX Quest Diagnostics | Maintains: Outperform | $203 → $210 | $179.50 | +16.99% | 3 | Oct 21, 2025 | |
| MCK McKesson | Maintains: Outperform | $785 → $850 | $851.99 | -0.23% | 15 | Sep 24, 2025 | |
| PINC Premier | Maintains: Underperform | $19 → $21 | $28.15 | -25.40% | 10 | Aug 19, 2025 | |
| CAH Cardinal Health | Maintains: Outperform | $188 → $186 | $203.67 | -8.68% | 13 | Aug 12, 2025 | |
| PGNY Progyny | Upgrades: Outperform | $28 | $22.37 | +25.17% | 11 | Jul 8, 2025 | |
| BOLD Boundless Bio | Downgrades: Market Perform | $15 → $3 | $1.22 | +146.91% | 2 | May 28, 2025 | |
| NVST Envista Holdings | Maintains: Buy | $26 → $23 | $19.45 | +18.25% | 11 | Apr 29, 2025 | |
| MEDP Medpace Holdings | Initiates: Market Perform | $330 | $589.15 | -43.99% | 1 | Mar 24, 2025 | |
| HIMS Hims & Hers Health | Maintains: Market Perform | $24 → $40 | $41.03 | -2.51% | 10 | Feb 25, 2025 | |
| CVS CVS Health | Upgrades: Outperform | $55 → $75 | $78.99 | -5.05% | 11 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $60 → $90 | $54.29 | +65.78% | 2 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $235 → $280 | $134.84 | +107.65% | 2 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $69 → $84 | $71.90 | +16.83% | 2 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $260 → $248 | $210.46 | +17.84% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $270 → $255 | $159.14 | +60.24% | 3 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $11.18 | - | 8 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $277 → $275 | $360.70 | -23.76% | 3 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $260 | $252.72 | +2.88% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $8 | $3.11 | +157.23% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $19 | $8.67 | +119.15% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $17 | $7.53 | +125.76% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $113 → $53 | $3.39 | +1,448.67% | 2 | Jan 5, 2022 |
Quest Diagnostics
Oct 21, 2025
Maintains: Outperform
Price Target: $203 → $210
Current: $179.50
Upside: +16.99%
McKesson
Sep 24, 2025
Maintains: Outperform
Price Target: $785 → $850
Current: $851.99
Upside: -0.23%
Premier
Aug 19, 2025
Maintains: Underperform
Price Target: $19 → $21
Current: $28.15
Upside: -25.40%
Cardinal Health
Aug 12, 2025
Maintains: Outperform
Price Target: $188 → $186
Current: $203.67
Upside: -8.68%
Progyny
Jul 8, 2025
Upgrades: Outperform
Price Target: $28
Current: $22.37
Upside: +25.17%
Boundless Bio
May 28, 2025
Downgrades: Market Perform
Price Target: $15 → $3
Current: $1.22
Upside: +146.91%
Envista Holdings
Apr 29, 2025
Maintains: Buy
Price Target: $26 → $23
Current: $19.45
Upside: +18.25%
Medpace Holdings
Mar 24, 2025
Initiates: Market Perform
Price Target: $330
Current: $589.15
Upside: -43.99%
Hims & Hers Health
Feb 25, 2025
Maintains: Market Perform
Price Target: $24 → $40
Current: $41.03
Upside: -2.51%
CVS Health
Feb 13, 2025
Upgrades: Outperform
Price Target: $55 → $75
Current: $78.99
Upside: -5.05%
Feb 7, 2025
Upgrades: Outperform
Price Target: $60 → $90
Current: $54.29
Upside: +65.78%
Jan 6, 2025
Upgrades: Outperform
Price Target: $235 → $280
Current: $134.84
Upside: +107.65%
Jan 6, 2025
Upgrades: Buy
Price Target: $69 → $84
Current: $71.90
Upside: +16.83%
Nov 19, 2024
Reiterates: Outperform
Price Target: $260 → $248
Current: $210.46
Upside: +17.84%
Nov 19, 2024
Reiterates: Outperform
Price Target: $270 → $255
Current: $159.14
Upside: +60.24%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $11.18
Upside: -
Oct 7, 2024
Maintains: Outperform
Price Target: $277 → $275
Current: $360.70
Upside: -23.76%
Feb 26, 2024
Initiates: Outperform
Price Target: $260
Current: $252.72
Upside: +2.88%
Feb 26, 2024
Initiates: Outperform
Price Target: $8
Current: $3.11
Upside: +157.23%
Feb 26, 2024
Initiates: Market Perform
Price Target: $19
Current: $8.67
Upside: +119.15%
Feb 26, 2024
Initiates: Market Perform
Price Target: $17
Current: $7.53
Upside: +125.76%
Jan 5, 2022
Downgrades: Underperform
Price Target: $113 → $53
Current: $3.39
Upside: +1,448.67%